No Data
No Data
Anika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Express News | Anika Therapeutics Inc : Stephens Raises Target Price to $24 From $22
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Call Transcript
Express News | Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Anika Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 32.14% Barrington Research $37 → $37 Maintains Outperform 03/14/2024 32.14% Barrington Research
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)